Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment

On:

Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.

Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.

Full results from the study are expected to be presented in 2023.

ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Satoshi-Era Bitcoin Whale Moves $1.2 Million Worth Of BTC After 13 Years
  2. Crypto Market Sentiment Muted Amidst Central Bank Reviews
  3. Silo Pharma Soars On Positive Data For Its Arthritis Drug Candidate
  4. Bitcoin And Ether Making A Major Bullish Turnaround, Trader Tells What To Expect
  5. Teledyne Drops As Profit Outlook Comes In Below View